Hypoxia-inducible factor 2 inhibitors show promise in advanced kidney cancer.
Accepted version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Abstract
A new phase I clinical trial has demonstrated that belzutifan provides a route to sustained inhibition of HIF-2α in humans that is well tolerated and could be useful in the treatment of advanced clear cell kidney cancer.
Description
Keywords
Basic Helix-Loop-Helix Transcription Factors, Humans, Kidney Neoplasms
Journal Title
Nat Rev Urol
Conference Name
Journal ISSN
1759-4812
1759-4820
1759-4820
Volume Title
18
Publisher
Springer Science and Business Media LLC
Publisher DOI
Rights
All rights reserved
Sponsorship
Wellcome Trust (096956/Z/11/Z)
NIHR Cambridge Biomedical Research Centre
Rosetrees Trust (no. G102721)